Inmedix CEO to Co-Chair Immuno-autonomics Study Group at 2018 Annual Meeting of the American College of Rheumatology.

Andrew J. Holman, MD, Inmedix CEO & Co-founder, to highlight how linkage between the brain and immune function adversely affects autoimmune disease treatment.

NORMANDY PARK, WA, USA, October 20, 2018 /EINPresswire.com/ — Inmedix, the leader in next-generation heart rate variability (HRV) application as an informative diagnostic tool in autoimmune disease, today announced that CEO & Co-founder, Andrew J. Holman, MD, will co-chair the ACR study group “Immuno-autonomics: Emerging Diagnostic & Therapeutic Advances in Rheumatology”” with Paul-Peter Tak, MD, PhD, Professor of Medicine, Academic Medical Center/University of Amsterdam, and former Chief Immunology Officer & Senior Vice President R&D Pipeline at GlaxoSmithKline (GSK) during ACR/ARHP Annual Meeting 2018, being held October 19-24, 2018 at the McCormick Place Convention Center, Chicago, IL.

Drs. Holman and Tak will be joined by Katherine Thanou, MD, Adjunct Professor of Medicine at the College of Medicine at the University of Oklahoma and Assistant Member of the Oklahoma Medical Research Foundation (OMRF), who will review her groundbreaking research related to immuno-autonomic HRV assessment in patients with systemic lupus erythematosus (SLE). The ACR/ARHP Study Group will be held in Room W196b at 1-2 pm on Monday, October 22, 2018.

Immuno-autonomics is the interface between stress, modulated within the brain by the autonomic nervous system (ANS), and the immune system. In autoimmune disease, the immune system attacks healthy tissues for reasons which remain unclear. Therapy is directed with various immunosuppressive strategies to reduce this inappropriate attack and potential destruction of joints, skin, kidney, brain, etc. (depending on the specific autoimmune disease).

Stress intensifies autoimmune disease, thereby reducing the effectiveness of current immunosuppressive options. This ACR/ARHP study group on immuno-autonomics is the third in the past four years. The lectures emphasize new opportunities to both accurately measure ANS stress and reduce its adverse effects to help rheumatologists restore the lives of patients with autoimmune diseases.

“Immuno-autonomics is a relatively new concept in medicine based on what our patients have been telling us for decades,” says Andrew J Holman, MD, Inmedix CEO, rheumatologist and Clinical Associate Professor of Medicine at the University of Washington. “Stress flares autoimmune disease to make it far less responsive to treatment. Understanding how and why may significantly enhance the way rheumatologists manage and even someday prevent autoimmune diseases.”

About Inmedix, Inc. and its subsidiary, Inmedix UK, Ltd.

Seattle-based biotech/medtech Inmedix, Inc. and its subsidiary Inmedix UK, Ltd. are committed to engaging in world class research to discover innovative solutions for pressing healthcare needs related to the impact of stress, modulated within the brain by the autonomic nervous system (ANS). The Inmedix ANS Neuroscan™ is leading applications of next-generation heart rate variability (HRV) as an informative diagnostic, therapeutic, digital health and health economic tool in autoimmune disease. ANS profile may be the most overlooked element of personalized, precision medicine. Beginning with rheumatoid arthritis (RA), psoriatic arthritis (PsA), systemic lupus erythematosus (SLE) and ankylosing spondylitis (AS) in adults, the company hopes to enhance current therapeutic outcomes through complimentary optimization of individual ANS profile.

Rae Marie Gleason
Education Program Director, Inmedix, Inc.
714-423-4863
email us here


Source: EIN Presswire

Two Ways Intermountain Healthcare Is Improving Access To Healthcare In Utah

SALT LAKE CITY, UTAH, USA, October 19, 2018 /EINPresswire.com/ — Intermountain Healthcare gives donations to many community partners to support its mission of helping people live the healthiest lives possible — and here are just two examples of recent community giving.

Intermountain made a $30,000 donation to the Kazan Clinic in rural Garfield and Wayne counties. Kazan Clinic is a member of the Behavioral Health Network, and its system of clinics serves uninsured or underpriviledged patients who need behavioral health services and referrals. Intermountain has helped support the clinic for about five years to enhance its care and staffing. Drop boxes for prescription medications have also been installed in the network for properly disposing unused or expired medication, which supports Intermountain's opioid misuse prevention work.

"Kazan Clinic has been very successful at helping more people get care much faster," says Debbie Hardy, community giving manager at Intermountain. "This partnership improves healthcare access to a wide area of Utah."

The Maliheh Free Clinic in Salt Lake City has received nearly $100,000 in Intermountain donations and grants since 2009. The clinic supports the uninsured with preventive care and patient education — specifically diabetes prevention. Intermountain gave a grant of more than $30,000 to their diabetes prevention clinic in May.

"The Maliheh Clinic has built a wonderful reputation for good care and education, particularly in the Pacific Islander population," says Hardy. "We've found Pacific Islanders feel safe attending classes and getting preventive treatment at the clinic."

Intermountain Healthcare is a Utah-based not-for-profit system of 23 hospitals, 170 clinics, a Medical Group with about 2,300 employed physicians and advanced practice clinicians, a health plans group called SelectHealth, and other medical services. Intermountain is widely recognized as a leader in transforming healthcare through high quality and sustainable costs. For more information about Intermountain, visit www.intermountainhealthcare.org.

Daron Cowley
Intermountain Healthcare
801-442-2834
email us here


Source: EIN Presswire

Muhammad Kaleem Arshad MD addresses the concepts and controversies regarding Attention Deficit Disorder

Dr M Kaleem Arshad

Dr. M Kaleem Arshad

Muhammad Kaleem Arshad MD, a board certified psychiatrist discusses the controversies surrounding ADD and attention deficit hyperactivity disorder (ADHD).

NEW ORLEANS, LOUISIANA, UNITED STATES, October 19, 2018 /EINPresswire.com/ — Muhammad Kaleem Arshad, a diplomate of American Board of Psychiatry and Neurology says that these controversies have surrounded this subject over last 50 years. The discussions in the medical field and general population have centered around the legitimacy of ADHD as mental disorder, its causes, prevalence and use of medications to treat the disorder, specifically stimulants.

Muhammad Kaleem Arshad MD indicates that the diagnosis of ADHD is accepted as legitimate in psychiatric profession based on the fact that the signs and symptoms of ADHD are persistent and rise to the degree where they affect individual’s ability to function in society. In some circles the very existence of this disorder or illness are being questioned and skeptics claim that the medical profession may have chosen to slap a label on the normal variant of human behavior. These critics feel that the symptoms attributed to ADHD are just extreme expressions of normal human behavior. There are very vocal critics who have called ADHD a fraud.

Muhammad Kaleem Arshad, MD who sees patients with this disorder in his practice, points out that some of these controversies exist because the diagnosis is based on entirely on the history of certain signs and symptoms without any objective tests. We can’t see ADHD on X Rays, scans, MRI ‘s, EEGs or laboratory tests. The same is true about multiple widely accepted psychiatric and neurological diagnoses. Only because we don’t see any readily grossly identifiable anatomical or pathological findings, we shouldn’t question the very existence of disorder. We can’t always see environmental stressors and biochemical changes on scans or slides.

It has been widely debated whether some of the differences seen in neuro-imaging of the brain like the thinning of cerebral cortex seen in patients really account for or explain the symptoms of ADHD. ADHD is inherited but but the environment does play a role. We are gradually beginning to accept that some interactions between genetics and the environment contributes to the disorder. Some have argued that ADHD may not be just one illness. It may stem from multiple genetic and environmental sources which converge to cause similar changes in the nervous system causing symptoms of disorder.

Muhammad Kaleem Arshad MD says that even if ADHD remains a fussy clinical entity, it is a general consensus that it is deficit of executive function mostly originating from frontal lobe in brain. This deficit affects a persons ability to pay attention, maintain focus, filter out distractions and control impulses.

Muhammad Kaleem Arshad MD says that there is significant debate concerning the prevalence of ADHD. Some experts believe that current rates still underestimate the prevalence of this disorder even if there have been significant increases in the rates that ADHD is being diagnosed in USA and United Kingdom.The increased environmental demands in this highly technological world and contemporary lifestyle changes may account for true increase in rates or just draw more attention to the symptoms. Some of the under diagnosis may be attributable to the stigma attached to being diagnosed with an illness at a young age and having to go on medications. Conversely some argue that disorder is being over diagnosed. Fairly general criteria for ADHD diagnosis lends to other disruptive behaviors and learning difficulties being diagnosed as ADHD. The subjective nature of assessments and reliance on self reports may lead to over-diagnosis as well. We need more research as to whether gender, socioeconomic status or racial biases influence prevalence rates.

Dr Muhammad Kaleem Arshad states that controversies around the use of psychotropic medication specifically stimulants. In the United States these medications are widely accepted means of treatment. Use of these medications increased almost 4 fold from 1987 to 1997. Over the last 10 years the rate of medication use has not increased. Frequently these medications are being used by non psychiatric physicians without a thorough assessment to establish a correct clinical diagnosis. The unnecessary or inappropriate use of these medications can actually cause more harm than good. Some would argue that while involvement of general practitioners in prescribing stimulants may have increased the access to care, it can actually lead to inappropriate use of these medications.

Muhammad Kaleem Arshad MD further elaborates that adverse reactions from the use of stimulants cause many parents to seek complementary or alternative treatments. Many individuals use complementary and alternative medicine (CAM) because they are attracted to CAM concepts and health beliefs, dissatisfied with the results of the conventional care with stimulants.

Use of these alternative approaches directly reflects on the complexity and heterogeneity of the disorder. Individualized dietary management and trace element supplementation may be beneficial in some children with ADHD. Self-regulatory techniques such as hypnotherapy and biofeedback do not alter the core symptoms of ADHD but may be helpful in controlling secondary symptoms. At present, nootropics, homeopathy and herbs are being researched regarding their role in neurologic regeneration but evidence to support their role in the specific treatment of ADHD is inconsistent.

Muhamnad Kaleem Arshad MD has practiced psychiatry in New Orleans area over last 30 years. He has directed several psychiatric hospitals and programs in the city .

Eric Ash
Web Presence, LLC
941-266-8620
email us here


Source: EIN Presswire

Life Care Planning: Post-Sanchez Decision

Dr. Greg Vigna

Dr. Greg Vigna

Sanchez adds an additional burden on Defense and Plaintiff Attorneys. Our experts in the trauma related medical fields have reduced this burden in time and expense to zero.”

— Dr. Greg Vigna

MODESTO, CALIFORNIA, UNITED STATES, October 19, 2018 /EINPresswire.com/ — Academic Physician Life Care Planning, LLC provides Sanchez proof testimony for its defense and plaintiff life care plans that relates to the anticipated cost of necessary future medical care by providing opinions in its life care plans from neurosurgeons, orthopedic surgeons, and Board-Certified physicians in Physical Medicine.

Historically, evidence that was presented to the jury that relates to the cost of future medical care for an injured person was provided by costing research obtained from sources that include CPT Codes (Current Procedural Terminology) and data obtained by phone calls to vendors (doctors, hospitals, equipment) of the actual cost charged for goods and services in the location where the injured person resides. California Evidence Code requires that an expert base their opinion on their ‘knowledge, skill, experience, education, and training’. In addition, California Evidence Code allow an expert to ‘state on direct examination the reasons for his opinion…., unless precluded by law from using such reasons.’

The Sanchez Decision by the California Supreme Court in June of 2016 has precluded a physician or nurse from relying on costing research provided for by this historic practice of obtaining cost data by life care planners, as this case has ruled that this testimony and reliance on these costing data essentially becomes ‘testimonial hearsay’ and is now barred by the confrontation clause of the Sixth Amendment.

Attorneys must now incur significant costs for expert opinions that independently can be relied upon a physician’s ‘skill, knowledge, experience, education, and training’ as it relates to the cost of future medical care. Non-catastrophic injuries such as disc herniations, rotator cuff tears, and knee injuries all have anticipated future care to patient’s life expectancy. Catastrophic injuries including traumatic brain injury, spinal cord injuries, burns, and amputations have future medical care in the millions. Plaintiff and defense attorneys must now get evidence of future care cost in by relying on experts with the ‘knowledge and experience’ that relates to cost.

Academic Physician Life Care Planning, LLC, led by Dr. Greg Vigna, provides Sanchez proof testimony by using neurosurgeons, orthopedic surgeons, prosthetic experts, trauma surgeons, plastic surgeons trained in burn care, and Board-Certified Physician in Physical Medicine Rehabilitation for its opinions that relate to all necessary future care and its cost, and life expectancy analysis. The physicians also have experience in fees related to facility fee cost.

Dr. Vigna adds, “Sanchez adds an additional burden on Defense and Plaintiff Attorneys. Academic Physician Life Care Planning, LLC, through its experts in the trauma related medical fields, has reduced this burden in time and expense to zero.”

Dr. Greg Vigna, owner of Academic Physician Life Care Planning, LLC, is a practicing attorney, Certified Life Care Planner, and Board-Certified Physician in Physical Medicine and Rehabilitation currently is the Medical Director of HealthSouth Modesto. Academic Physician Life Care Planning, LLC provides this service with no additional cost for its defense and plaintiff life care plans.

Greg Vigna
Greg Vigna, M.D., J.D.
1-800-761-9206
email us here


Source: EIN Presswire

Miles Clark, Director Of Clinical Research for Clinical Based Research Company, Excited To Be A Part of Waite Enterprise

Waite Enterprise CEO Daniel Waite working closely with Miles Clark to build out the health sector of Corporate Holdings.

DALLAS, TX, USA, October 19, 2018 /EINPresswire.com/ — Clinical Based Research is a successful clinical research organization based in Dallas, TX. The company is currently moving in to the new Waite Enterprise corporate headquarters facilities in Dallas, and is part of Daniel Waite and the company’s leadership’s long term diversification planning. The company is an emerging leader in the clinical studies data sector of the health industry.

“Clinical based research is more than a great company. CBR provides great services in an area of need.” Waite Enterprise CEO Daniel Waite explains. “CBR focuses on post market clinical research as well as phase trials. Clinical Based Research is excited to announce Miles Clark as the director of clinical research. Miles has a background in finance, clinical research and other sectors as well. He has 8 years in the post market clinical research and phase trials. Also several years with a billion dollar hedge fund. He is simply a leader in a strong sector for this company who understands the bigger picture. He is a specialist in his field but he understands the larger aspects of finance and investing and leveraging.

“That is really what we are building here, quality people and leadership that provide great guidance and insight so that we stay ahead of the field. When you boil it down, what is a company anyway but its people? You think of Ford you think of cars and trucks but it started with Henry Ford and his vision. You think of Apple you think of technology devices but it started with Steve Jobs and his vision and drive. We are building a company filled with diverse leadership, expertise and skill sets. So sure we will hold diverse physical assets like gold and Bitcoin and real estate to leverage profits against financial and economic turmoil, but we are adding leaders like Miles and Roberto Saenz and Larry Pickett that are worth more than all the gold and BTC in the universe. Waite Enterprise with visionaries and leaders like Miles is becoming a diverse business leadership and innovation basket. That is the long term goal. Not to just have the gold to cover economic hardships, to have the leaders that can help us fix the economic hardship in the first place. The investments will just buy them the time they need to develop and implement strategies and get to work.”

About Waite Enterprise:

Waite Enterprise (subsidiary of Waite Capital, Inc.) is a diversified holding company with a vast platform of subsidiaries and investments that leverage resources and growth from various sectors, currencies and assorted commodities, from cryptocurrency to real estate to high end vehicles. The company is being developed by Daniel Waite with the intention of ultimately going public, offering a diversified investment platform designed as a basket that provides revenue streams from digital platforms, currencies, and businesses in the construction, healthcare and financial fields.

About Clinical Based Research:

Clinical Based Research is a clinical research organization that focuses on post market clinical research as well as phase trials. The company is headquartered in Dallas, Texas and is expanding throughout the Southwest region of the United States.

don eminizer
Smoulder Pro
717-387-5149
email us here


Source: EIN Presswire

Donna L. Lauck of Collaborative Care to be Featured on CUTV News Radio

ABINGTON, PENNSYLVANIA, UNITED STATES, October 19, 2018 /EINPresswire.com/ — Donna L. Lauck is one of those people who is proud to say she became what she wanted to be as a child. From the time she could talk, Donna told everyone she wanted to be a Nurse. Today, she is not only a Nurse, she’s an Advanced Practice Nurse (APRN) with a Doctoral degree (DNSc) and a specialization in Psychology. She’s also an integral part of a team approach to healing at the only holistic care center in her area. At Collaborative Care of Abington (in Montgomery County, just outside Philadelphia), Donna draws on her nursing instincts, her compassion for humanity, and her 25-plus years of experience, to help balance all the physical, emotional and neurological sides of an individual.

Donna wants to publicize that people with mood or mental health issues are, after all, just people. There is no reason to degrade them, and there is no reason for anyone to feel ashamed about treatment. Like anything else that affects the body and causes illness, you just need to go and get if fixed! Depending on the individual, fixing might include energy therapy modalities, such as Reiki or IET. Donna may also use hypnosis, classic cognitive behavioral approaches or a special self-esteem program. Donna often assigns clients homework, to help in their therapeutic goals. The modality and approach she’ll choose has a lot to do with the individual and their needs.

Donna credits her knowledge of such advanced and integrative therapies to the many teachers and influencers throughout her career. One big one is C. Norman Shealy, often called Norm, an MD and Psychologist recognized as a pioneer in pain management and alternative healing. Together with his colleague, Carolyn Myss, who is a medical intuitive, he founded a Graduate Seminary at HOLOS University, the first all-holistic medical college. Donna has taken some of their classes and it enables her to treat the many aspects of an individual and inspire wellness.

Donna isn’t sure if it’s an inborn sensitivity or something education inspired, but she does have a talent for evaluating behaviors, offering support, and getting clients to participate in their own self-care. She also really loves working in a setting where the staff is so supportive of one another–offering back-up, insights, and opinions–and practicing a cohesive and well-rounded approach to health and comfort. It’s so collaborative, like their name says, and this kind of practice can also be referred to as mindful care. Donna says that aside from mental health issues, this type of treatment works wonders for stress relief and relaxation, which is essential in a bustling city like Abington.

If you noticed Donna’s e-mail address it refers to her as a Golf Doctor. While she could use therapeutic techniques to help one improve their focus and game, the main reason is her lifelong love of golf. Donna doesn’t play as much since her husband passed on, but still loves the sport, and frequently takes on her son.

CUTV News Radio will feature Doctor Donna L. Lauck in an interview with Jim Masters on Tues, Oct 23 at 1:00pm EDT

Listen to the show on BlogTalkRadio

If you have questions for our guest, please call (347)996-3369

Lou Ceparano
CUTV News
(631) 850-3314
email us here
Visit us on social media:
Facebook


Source: EIN Presswire

Arizona Mesothelioma Victims Center Now Urges a Public Utility or Power Plant Worker with Mesothelioma in Arizona to Call Them for Direct Access to the Nation's Top Lawyers for Better Financial Compensation Results

We provide immediate access to the nation's top mesothelioma attorneys who consistently get the best compensation for their clients.”

— Arizona Mesothelioma Victims Center

NEW YORK, NEW YORK, USA, October 19, 2018 /EINPresswire.com/ — The Arizona Mesothelioma Victims Center says, "We are urging a nuclear power, public utility, electric, water, or natural gas worker who has recently been diagnosed with mesothelioma in Arizona to call us anytime at 800-714-0303 to ensure they are talking directly with some of the nation's most skilled and experienced mesothelioma attorneys. We specialize in assisting public utility and power/energy workers who have been diagnosed with mesothelioma in Arizona and nationwide. Our number one priority is making certain people like this receive the very best possible financial compensation-which could exceed a million dollars." http://Arizona.MesotheliomaVictimsCenter.Com

The Arizona Mesothelioma Victims Center fears the Internet makes the process of getting direct access to the nation's top mesothelioma attorneys next to impossible. As the group would like to discuss anytime at 800-714-0303, "We provide immediate access to the nation's top mesothelioma attorneys who consistently get the best compensation for their clients. There is a direct connection between hiring the nation's most skilled, experienced, and capable full-time mesothelioma attorneys and the person with mesothelioma receiving the best possible financial compensation settlement result." http://Arizona.MesotheliomaVictimsCenter.Com

For more information about public utilities or energy companies in Arizona please visit an Arizona website on these topics: http://www.azcc.gov/divisions/utilities/

For the best possible mesothelioma treatment options in Arizona the Arizona Mesothelioma Victims Center strongly recommends the following heath care facilities with the offer to help a diagnosed victim, or their family get to the right physicians at each hospital.

* The Mayo Clinic Phoenix/Scottsdale, Arizona: http://www.mayoclinic.org/departments-centers/mayo-clinic-cancer-center

* The University of Arizona Medical Center Tucson, Arizona:
http://azcc.arizona.edu/profile/linda-garland.

The Arizona Mesothelioma Victims Center would like to emphasize theirs is a statewide initiative available to a diagnosed victim anywhere in Arizona including communities such as Phoenix, Tucson, Mesa, Chandler, Glendale, Gilbert, Tempe. Peoria, or Prescott. http://Arizona.MesotheliomaVictimsCenter.Com

High-risk work groups for exposure to asbestos in Arizona include US Navy Veterans, power plant workers, manufacturing workers, plumbers, nuclear power plant workers, electricians, auto mechanics, machinists, or construction workers. Typically, these high-risk workers were exposed to asbestos in the 1950’s, 1960’s, 1970’s, or 1980’s.

The states indicated with the highest incidence of mesothelioma include Maine, Massachusetts, Connecticut, Maryland, New Jersey, Pennsylvania, Ohio, West Virginia, Virginia, Michigan, Illinois, Minnesota, Louisiana, Washington, and Oregon. Mesothelioma also happens in Arizona. http://Arizona.MesotheliomaVictimsCenter.com

For more information about mesothelioma please refer to the National Institutes of Health’s web site related to this rare form of cancer: https://www.cancer.gov/types/mesothelioma

Michael Thomas
Arizona Mesothelioma Victims Center
800-714-0303
email us here


Source: EIN Presswire

American Gene Technologies Granted FDA Orphan Drug Designation For Phenylketonuria

ROCKVILLE, MD, UNITED STATES, October 18, 2018 /EINPresswire.com/ — American Gene Technologies (AGT), a leading gene and cell therapy company in the discovery and development of lentiviral vector based therapeutics, announces that the U.S. Food and Drug Administration (FDA) received orphan-drug designation #DRU-2018-6572 for the treatment of phenylketonuria (PKU) using its proprietary, lentiviral vector based technology. PKU is a debilitating inherited disease affecting 1 in 13,500 children born in the U.S. Mandatory screening identifies affected children who can be supported with a strict synthetic diet that does not cure disease. If successful, AGT's lentiviral vector approach will provide a permanent cure, improving quality of life for more than 16,000 people living with PKU in the U.S. alone.

“We are pleased to receive this orphan drug designation from the FDA for AGT’s vector technology to treat PKU. Our technology demonstrates promising potential to address an unmet medical need in treating this rare disease,” said Jeff Galvin, CEO and Founder of AGT. “We believe this orphan designation will enable AGT to formally shape and advance its PKU program.”

About American Gene Technologies (AGT):

AGT is an emerging gene and cell therapeutics company with a proprietary lentiviral platform capable of broad applications including: large and orphan indications, infectious disease, immune-oncology, and monogenic disorders. AGT expects to take its patented, lead candidate for an HIV Cure into the clinic in 2019. It has pioneered a novel immuno-oncology approach of stimulating gamma-delta (γδ) T cells to attack a variety of cancers. Four key patents in AGT’s novel immuno-oncology approach have been granted. AGT has a diverse portfolio of patent filings surrounding key tools and components in viral vectors, gene therapy, and regenerative medicine.

Website: www.americangene.com

American Gene Technologies Contacts:

C. Neil Lyons, Chief Financial Officer
Phone: (301) 337-2269
Email: info@americangene.com

Media Contact: Sasha Whitaker, swhitaker@americangene.com
American Gene Technologies
(301) 337-2100
email us here


Source: EIN Presswire

NEXIEN BioPharma Inc. Announces Symbol Change to NXEN

Nexien BioPharma's new trading symbol: NXEN

Nexien BioPharma Inc (OTCQB:NEXN)

The new symbol, NXEN, is more reflective of our Corporate name, Nexien BioPharma and our objective of being a global leader in the cannabinoid science and the development of pharmaceuticals”

— Alain Bankier, Interim CEO

DENVER, CO, USA, October 18, 2018 /EINPresswire.com/ — Nexien BioPharma Inc. (OTCQB: NXEN) (formerly Intiva BioPharma Inc.) (the "Company") today announced that effective as of October 19, 2018, the Company will trade on the OTC QB under the new stock symbol NXEN.

Commenting on the symbol change, Alain Bankier, the Interim CEO of Nexien stated, “ The new symbol, NXEN, is more reflective of our Corporate name, Nexien BioPharma and our objective of being a global leader in the further evolution of cannabinoid science and the development of Food and Drug Administration ("FDA") compliant pharmaceuticals based on specific cannabinoid molecules.”
About Nexien BioPharma
Nexien BioPharma is a US-based pharmaceutical development company engaged in the formulation, development, and commercialization of cannabinoid-based pharmaceuticals in accordance with U.S. Food and Drug Administration ("FDA") pre-clinical and clinical pathways, to address a broad range of medical conditions and disorders.
Nexien BioPharma's drug development strategy consists of:
• The determination of medical conditions and disorders that could potentially benefit from cannabinoid-based formulations;
• Conducting "freedom to operate" investigations on these conditions;
• The preparation of patent applications and the prosecution of such application and/or the licensing of existing patents;
• Identifying the regulatory pathway with the FDA; and
• Proceeding with pre-clinical and clinical development activities in accordance with FDA protocols for submission to obtain approval for the particular product(s).
Current financial disclosure and Real-Time Level 2 quotes for Nexien Biopharma are available at www.otcmarkets.com or at www.INTIVABioPharma.com.

Nexien Disclosure Notice: This press release contains "forward-looking statements. For this purpose, any statements contained herein or which are otherwise made by or on behalf of Nexien BioPharma that are not statements of historical facts may be deemed forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "should," "would," "estimate," or "continue," or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements. Readers are cautioned that all forward-looking statements involve risk and uncertainties, which may cause results to differ materially from those, set forth in the statements. Such risks and uncertainties include, but are not limited to the following: the success of research and development activities and the speed with which regulatory authorizations and product launches may be achieved; government regulation generally; competitive developments; the ability to successfully market products domestically and internationally; difficulties or delays in manufacturing or issues relating to manufacturing capacity; commercial obstacles to the successful introduction of brand products generally; legal defense costs, insurance expenses, settlement costs, and the risk of an adverse decision or settlement relating to product liability, patent protection, governmental investigations, and other legal proceedings; Nexien BioPharma's ability to acquire and protect patents and other intellectual property both domestically and internationally; the absence of certainty regarding the receipt of required regulatory approval or the timing or terms of such approvals; any changes in business, political and economic conditions; business interruption due to events outside of Nexien BioPharma's control.
Readers are cautioned not to place reliance on these forward-looking statements, which are valid only as of the date they were made. Nexien BioPharma undertakes no obligation to update or revise any forward-looking statements to reflect new information or the occurrence of unanticipated events or otherwise, except as expressly required by law.

Mark Lubchenco
Nexien BioPharma Inc
303 495 7583
email us here


Source: EIN Presswire

The My Freedom Lift Bed provides Independence to Millions In Need

A bed that converts into a lift chair and safely puts your loved one or patient in bed and allows them to get out of bed without help.

I have never seen a product with the benefits of The My Freedom Lift Bed. ROI is not only measured in dollars but also in reducing liability & risk of patient injury as well as reducing labor costs.”

— John Oviatt

ORLANDO, FL, UNITED STATES, October 18, 2018 /EINPresswire.com/ — After successful completion and extended product testing and evaluation, HMS has secured a nationwide exclusive distribution agreement for the My Freedom Lift Bed. Being first to market, The My Freedom Lift Bed artfully combines the benefits of a lift chair with a fully electric hospital bed. The Advanced model retails at $7,995 and is equipped with the GreatCall® monitoring system and also offers an optional air adjustable mattress topper to maximize patient comfort.

Neither Traditional hospital beds or leisure consumer adjustable beds provide for ease of transfer to a standing position and often require assistance from others. Lift chairs do not provide the support and comfort of a luxury mattress which makes sleeping or even spending an extended amount of time in them problematic for many. The My Freedom Lift Bed combines the ease of standing with a lift chair and the comfort of a leisure adjustable bed with the Hi-Lo feature of a fully electric hospital bed at one low attractive price. The Advanced model is backed with a ten-year limited warranty. Monthly rental programs are also available.

Over 1.5 million people currently reside in nursing homes nationwide. New regulations mandating a minimum of two staff members to assist a resident out of bed for transfer will add millions to institutional staffing costs. The My Freedom Lift Bed can eliminate the need for the two-person assistance requirement as well as allow the patient or resident their freedom and pride with unassisted entry and exit from the bed.

Being a Florida based company, HMS selected Orlando, Tampa, St. Pete Florida as the first markets to launch the new My Freedom Lift Bed Basic and Advanced model. With nearly 2,000 Assisted Living Centers in Florida, Central Florida is home to many of the top rated Assisted Living and Skilled Nursing Home facilities providing a unique opportunity to market the My Freedom Lift Bed. The response has been overwhelming and there is now a wait list for the next supply arriving in early December. HMS greatly underestimated the acceptance of the My Freedom Lift Bed and has stepped up production to match the increasing demand.

Tom Wasman
HMS Guest Experience
321-800-2121
email us here


Source: EIN Presswire